Join Diamyd Medical’s Clinical Trial and Discover the Benefits of GAD-65 Therapy
If you or someone you know has been diagnosed with type 1 diabetes within the previous six months and is between the ages of 12 and 29, there is a chance to take part in Diamyd Medical’s clinical trial for GAD-65 therapy.
What is GAD-65?
Consider the immune system in your body as a security staff that keeps invaders from entering your home.
Sometimes, this security staff gets confused and starts attacking the good guys who live in the house.
In people with type 1 diabetes, the immune system (security staff) gets mixed up and starts attacking the cells in the pancreas that make insulin.
Diamyd developed a therapy called GAD-65 that basically tells your immune system to stop attacking and destroying the cells that produce insulin.
Diamyd’s GAD-65 therapy is like giving the security staff a new set of instructions.
How GAD-65 Works?
Introduction of GAD-65
- A tiny amount of GAD-65 is administered to your body as part of the therapy.
- This instructs your immune system to cease targeting the cells that produce insulin.
Training the Immune System
Consider it as a way to teach the “security staff” that these cells are allies rather than enemies.
Protecting Insulin Production
- By stopping the attacks, the cells in your pancreas can keep making insulin.
- This means you might not need as much insulin from shots or an insulin pump.
Gene Check
- Scientists found that GAD-65 works best in people with a specific gene.
- About 40% of people with type 1 diabetes have this gene.
- If you have it, the therapy is more likely to help you.
What Can Be Expected From Diamyd’s Clinical Trial?
If you qualify for Diamyd’s clinical trial, you will receive three injections of GAD-65 over three months.
After the treatment phase, there will be a follow-up period lasting about 22 months with occasional blood tests to monitor your progress.
Safety and Efficacy
So far, the GAD-65 therapy has shown promising results.
Previous studies found that C-peptide (an indicator of insulin production) was significantly preserved compared to placebo in those with a particular gene. In the phase III trial, DIAGNODE-3, only people with this particular gene are treated
How Do I Sign Up for Diamyd’s Clinical Trial?
Diamyd is recruiting participants in a dozen locations across the United States and several European countries.
Visit Diagnode-3.com or email ClinicalTrials@Diamyd.com to learn more!
